| NCT06592768 | A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma | TERMINATED | PHASE1 | 2024-11-26 | 2025-08-11 | 2025-08-11 |
| NCT06736262 | A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria Trials | ENROLLING_BY_INVITATION | PHASE2 | 2024-11-26 | 2026-12-01 | 2026-12-01 |
| NCT06353971 | A Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients With Chronic Inducible Urticaria (CIndU) Who Remain Symptomatic Despite Treatment With H1- Antihistamines | TERMINATED | PHASE1, PHASE2 | 2024-03-18 | 2025-07-31 | 2025-07-31 |
| NCT06162728 | Dose Escalation Trial of Safety, Pharmacokinetic/Pharmacodynamic and Preliminary Clinical Activity of Briquilimab in Adult Patients with Chronic Spontaneous Urticaria (CSU) | RECRUITING | PHASE1, PHASE2 | 2023-11-29 | 2026-04-01 | 2026-04-01 |
| NCT05903274 | JSP191 (briquilimab) in Subjects with LR-MDS | TERMINATED | PHASE1 | 2023-06-19 | 2024-10-21 | 2024-10-21 |
| NCT04429191 | JSP191 Antibody Conditioning Regimen in MDS/AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation | UNKNOWN | PHASE1 | 2020-07-08 | 2023-12-08 | 2023-10-15 |
| NCT02963064 | JSP191 Antibody Targeting Conditioning in SCID Patients | TERMINATED | PHASE1, PHASE2 | 2017-03-20 | 2025-07-07 | 2025-07-07 |